Elena Nikulina

Biomea Fusion reports 52 percent C peptide AUC gain in Phase 2 diabetes trial at week 12

Biomea Fusion reports 52 percent C peptide AUC gain in Phase 2 diabetes trial at week 12
Biomea Fusion posts diabetes trial gains

Biomea Fusion has announced positive 52 week results from its Phase 2 COVALENT 112 trial, which is evaluating icovamenib in patients with type 1 diabetes.

The company reported a 52 percent increase in mean C peptide area under the curve at week 12, with the effect largely maintained through week 52, experiencing only a 7 percent decline after the initial 12 weeks of dosing. These findings suggest sustained efficacy of icovamenib over a full year. More details on the clinical implications and next development steps are awaited.

Biomea Fusion previously outlined key milestones for icovamenib, with COVALENT trial data projected for 2026 in its development timeline. The company has also reported that diabetes remains poorly controlled in many patients despite standard therapies. These background factors provide context for the latest 52-week efficacy results.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.